Suppr超能文献

韩国大学医院中用于哮喘治疗的口服皮质类固醇的处方模式及相关哮喘表型

Prescription Patterns of Oral Corticosteroids for Asthma Treatment and Related Asthma Phenotypes in University Hospitals in Korea.

作者信息

Kwon Jae-Woo, Kim Mi-Ae, Sim Da Woon, Lee Hwa Young, Rhee Chin Kook, Yang Min-Suk, Shim Ji-Su, Kim Min-Hye, Kim So Ri, Park Chan Sun, Kim Byung-Keun, Kang Sung-Yoon, Choi Gil-Soon, Lee Hyun, Jang An-Soo, Kim Sang-Heon

机构信息

Division of Allergy and Clinical Immunology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.

Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.

出版信息

Allergy Asthma Immunol Res. 2022 May;14(3):300-313. doi: 10.4168/aair.2022.14.3.300.

Abstract

PURPOSE

Oral corticosteroids (OCSs) are frequently prescribed for asthma management despite their adverse effects. An understanding of the pattern of OCS treatment is required to optimize asthma treatment and reduce OCS usage. This study evaluated the prescription patterns of OCSs in patients with asthma.

METHODS

This is a retrospective multicenter observational study. We enrolled adult (≥18 years) patients with asthma who had been followed up by asthma specialists in 13 university hospitals for ≥3 years. Lung function tests, the number of asthma exacerbations, and prescription data, including the days of supply and OCS dosage, were collected. The clinical characteristics of OCS-dependent and exacerbation-prone asthmatic patients were evaluated.

RESULTS

Of the 2,386 enrolled patients with asthma, 27.7% (n = 660) were OCS users (the median daily dose of OCS was 20 mg/day prednisolone equivalent to a median of 14 days/year). OCS users were more likely to be female, to be treated at higher asthma treatment steps, and to show poorer lung function and more frequent exacerbations in the previous year than non-OCS users. A total of 88.0% of OCS users were treated with OCS burst with a mean dose of 21.6 ± 10.2 mg per day prednisolone equivalent to 7.8 ± 3.2 days per event and 2.4 times per year. There were 2.1% (51/2,386) of patients with OCS-dependent asthma and 9.5% (227/2,386) with exacerbation-prone asthma. These asthma phenotypes were consistent over the 3 consecutive years in 47.1% of OCS-dependent asthmatic patients and 34.4% of exacerbation-prone asthmatic patients when assessed annually over the 3-year study period.

CONCLUSIONS

We used real-world data from university hospitals in Korea to describe the OCS prescription patterns and relievers in asthma. Novel strategies are required to reduce the burden of OCS use in patients with asthma.

摘要

目的

尽管口服糖皮质激素(OCS)存在不良反应,但在哮喘治疗中仍经常被处方使用。为了优化哮喘治疗并减少OCS的使用,需要了解OCS的治疗模式。本研究评估了哮喘患者中OCS的处方模式。

方法

这是一项回顾性多中心观察性研究。我们纳入了在13所大学医院接受哮喘专科医生随访≥3年的成年(≥18岁)哮喘患者。收集了肺功能测试、哮喘发作次数以及包括供应天数和OCS剂量在内的处方数据。评估了依赖OCS和易发作哮喘患者的临床特征。

结果

在2386名纳入的哮喘患者中,27.7%(n = 660)为OCS使用者(OCS的每日中位剂量为20毫克/天泼尼松龙,相当于每年中位使用14天)。与非OCS使用者相比,OCS使用者更可能为女性,处于更高的哮喘治疗级别,且在前一年肺功能较差、发作更频繁。共有88.0%的OCS使用者接受了OCS冲击治疗,平均剂量为21.6±10.2毫克/天泼尼松龙,每次事件相当于7.8±3.2天,每年2.4次。有2.1%(51/2386)的患者患有依赖OCS的哮喘,9.5%(227/2386)的患者患有易发作哮喘。在为期3年的研究期间每年进行评估时,47.1%的依赖OCS的哮喘患者和34.4%的易发作哮喘患者在连续3年中这些哮喘表型保持一致。

结论

我们利用韩国大学医院的真实世界数据描述了哮喘患者中OCS的处方模式和缓解药物。需要新的策略来减轻哮喘患者使用OCS的负担。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/044e/9110914/bae92426d79f/aair-14-300-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验